Article Text

Download PDFPDF

Highlights from this issue
  1. Andrew Bush,
  2. Ian Pavord, Editors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Back to basics!

This unfortunate exhortation is usually the prelude to an outbreak of financial and sexual chicanery which would have caused comment even in the declining years of Imperial Rome (although not perhaps today in the same city). But this is the current exciting cystic fibrosis (CF) rallying cry. The treatment of CF has traditionally been fire fighting—treat the downstream consequences of cystic fibrosis transmembrane regulator (CFTR) dysfunction, like infection, inflammation and mucus hypersecretion. In the more than 20 years since the discovery of the CF gene, a series of focused studies have led to profound discoveries of the basic biology of CFTR and therefore to specific designer therapies to correct the basic defect, discovered by high-throughput screening of thousands of compounds. G551D CFTR reaches the apical cell membrane but functions abnormally. The ‘potentiator’ VX-770 has been shown to have dramatic effects in CF patients with this rare mutation (about 5% of the population), for example, halving sweat chloride (see NEJM 2011;365:1663-72). The most common mutation, ΔF508, results in a protein which is largely destroyed in the endoplasmic reticulum. Clancy et al (Hot topic: see page 12) report on VX-809, a ‘corrector’ designed to allow the mutant protein to escape the endoplasmic reticulum and reach the cell surface. The medication was safe and there was a small, dose-dependent fall in sweat chloride, although an order of magnitude less than VX-770. Stuart Elborn reviews how translational science is changing the face of CF therapy in an accompanying editorial (see page 4). A note of caution—one of the lessons of the failure of denufosol, a CF medication for which there was an excellent theoretical basis for efficacy, is that we must not get too excited too soon about relatively small changes. However, CF is an area where treatments are being found in translation.

FEV1 and the chest physician

Chest physicians are as attached to FEV1 as diabetologists are to HbA1c. However, as diabetologists have learnt with HbA1c, we should be cautious about extrapolating changes in FEV1 to long-term benefit as very different mechanisms could be responsible for the change. The FACET study (see NEJM 1997;337:1405-11) showed that the large improvement in FEV1 seen after addition of formoterol to low-dose inhaled budesonide was associated with a small reduction in the risk of subsequent asthma attacks. The opposite was seen with a fourfold increased dose of budesonide. Two opinion pieces in this issue of Thorax highlight other issues with FEV1. Dirkje Postma and colleagues (see page 88) argue convincingly that demonstration of irreversible airflow obstruction is hopelessly inadequate for disease diagnosis. We must insist on more than this. How much more informative is ‘this patient has symptoms as a result of fixed airflow obstruction associated with a 20 pack year smoking history and eosinophilic, potentially steroid responsive airway inflammation’ compared with ‘this patient has COPD’? Guy Marks (see page 85) argues that a low FEV1 and FEV1/FVC should be viewed as a risk factor along with other variables, and used to predict the likelihood of future clinically significant and potentially preventable events such as the onset of symptoms and the development of lung attacks. Both opinions raise the vexed question of definitions of abnormality, an argument that will never be resolved to the satisfaction of all. IP, for one, would be quite happy with a diagnosis of ‘irreversible airflow obstruction associated with ageing’. AB is in denial about ageing.

The early worm gets the bird

We have long known that it is a bad thing to be born very early, even if you escape without the need for heroic intensive care, because there is increased morbidity and persistent airflow obstruction. However, the ‘late pretermers’ (born at 33–34 weeks' gestation) have slipped under the radar. Kotecha and colleagues (Editors' choice: see page 54) used the ALSPAC cohort to show that 33–34-week gestation babies had similar decrements in lung function at age 8–9 years as those born at 25–32 weeks, each group showing a further incremental decrease in those ventilated. By contrast, results in the 35–36-week gestation babies were the same as term controls. By age 17, there had been some catch-up in the late preterms, but spirometry was still abnormal. What will happen when these lungs start to age? Is this another high-risk group for premature airflow obstruction?

The late response to allergen and airway nerves

Here's another observation on FEV1. The same fall in FEV1 seen after allergen challenge during the early and late response is associated with marked differences in symptoms (severe distress during early response, mild ‘chestiness’ during the late), response to β2 agonists (good during the early response, poor during the late) and inflammation (marked eosinophilia after a late response, mast cell degranulation during the early). Clearly different mechanisms are involved. Raemdanck and colleagues (see page 19) make the interesting observation that the late response is blocked by general anaesthetic in sensitised rats. This probably occurred as a result of sensory nerve inhibition as other agents active against airway nerves, including tiotropium, had a similar inhibitory effect. Is this another example of a misleading animal model of asthma? We await clinical trials of tiotropium against allergen-induced asthma in humans with interest.

View Abstract

Linked Articles